Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $567.43 million. The enterprise value is $626.49 million.

Market Cap	567.43M
Enterprise Value	626.49M

Important Dates

The last earnings date was Friday, November 8, 2024, before market open.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 128.67 million shares outstanding. The number of shares has increased by 9.01% in one year.

Current Share Class	128.67M
Shares Outstanding	128.67M
Shares Change (YoY)	+9.01%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	9.22%
Owned by Institutions (%)	28.31%
Float	94.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	28.02
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.10

Current Ratio	1.10
Quick Ratio	0.98
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-13.24

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-53.23%
Return on Capital (ROIC)	-128.12%
Revenue Per Employee	n/a
Profits Per Employee	-$826,308
Employee Count	185
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +75.00% in the last 52 weeks. The beta is 1.47, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	1.47
52-Week Price Change	+75.00%
50-Day Moving Average	5.36
200-Day Moving Average	5.39
Relative Strength Index (RSI)	35.39
Average Volume (20 Days)	3,265,831

Short Selling Information

The latest short interest is 17.25 million, so 13.41% of the outstanding shares have been sold short.

Short Interest	17.25M
Short Previous Month	16.68M
Short % of Shares Out	13.41%
Short % of Float	18.33%
Short Ratio (days to cover)	5.35

Income Statement

Revenue	n/a
Gross Profit	-77.40M
Operating Income	-112.49M
Pretax Income	-105.70M
Net Income	-152.87M
EBITDA	-105.28M
EBIT	-112.49M
Earnings Per Share (EPS)	-$1.36

Full Income Statement

Balance Sheet

The company has $20.57 million in cash and $79.64 million in debt, giving a net cash position of -$59.06 million or -$0.46 per share.

Cash & Cash Equivalents	20.57M
Total Debt	79.64M
Net Cash	-59.06M
Net Cash Per Share	-$0.46
Equity (Book Value)	-63.72M
Book Value Per Share	-0.53
Working Capital	2.06M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$90.60 million and capital expenditures -$1.66 million, giving a free cash flow of -$92.26 million.

Operating Cash Flow	-90.60M
Capital Expenditures	-1.66M
Free Cash Flow	-92.26M
FCF Per Share	-$0.72

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.01%
Shareholder Yield	-9.01%
Earnings Yield	-26.94%
FCF Yield	-16.26%

Analyst Forecast

The average price target for Humacyte is $12.71, which is 188.21% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.71
Price Target Difference	188.21%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1